Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 17% Improvement Relative Risk HCQ for COVID-19  Tu et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 180 patients in Sierra Leone (March - August 2020) Study underpowered to detect differences c19hcq.org Tu et al., Infectious Diseases & Immun.., Jan 2022 Favors HCQ Favors control

Risk Factors for Severity and Mortality in Adult Patients Confirmed with COVID-19 in Sierra Leone: A Retrospective Study

Tu et al., Infectious Diseases & Immunity, doi:10.1097/ID9.0000000000000037
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 180 hospitalized COVID-19 patients in Sierra Leone, showing no significant difference with HCQ treatment in unadjusted results, however HCQ was significantly more likely to be used for severe patients (33% vs. 12%).
Although the 17% lower mortality is not statistically significant, it is consistent with the significant 24% lower mortality [20‑29%] from meta analysis of the 249 mortality results to date.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
Study covers HCQ and vitamin C.
risk of death, 17.2% lower, RR 0.83, p = 0.81, treatment 6 of 37 (16.2%), control 28 of 143 (19.6%), NNT 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tu et al., 13 Jan 2022, retrospective, Sierra Leone, peer-reviewed, 11 authors, study period 31 March, 2020 - 11 August, 2020. Contact: cww302@126.com, jjzheng@vip.sina.com, stevesyllo@gmail.com.
This PaperHCQAll
Risk Factors for Severity and Mortality in Adult Patients Confirmed with COVID-19 in Sierra Leone: A Retrospective Study
Bo Tu, Sulaiman Lakoh, Biao Xu, Marta Lado, Reginald Cole, Fang Chu, Susan Hastings-Spaine, Mohamed Bole Jalloh, Junjie Zheng, Weiwei Chen, Stephen Sevalie
Infectious Diseases & Immunity, doi:10.1097/id9.0000000000000037
Background: The coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease. There is no recommended antiviral treatment approved for COVID-19 in Sierra Leone, and supportive care and protection of vital organ function are performed for the patients. This study summarized the clinical characteristics, drug treatments, and risk factors for the severity and prognosis of COVID-19 in Sierra Leone to provide evidence for the treatment of COVID-19. Methods: Data of 180 adult COVID-19 patients from the 34th Military Hospital in Freetown Sierra Leone between March 31, 2020 and August 11, 2020 were retrospectively collected. Patients with severe and critically ill are classified in the severe group, while patients that presented asymptomatic, mild, and moderate disease were grouped in the non-severe group. The clinical and laboratory information was retrospectively collected to assess the risk factors and treatment strategies for severe COVID-19. Demographic information, travel history, clinical symptoms and signs, laboratory detection results, chest examination findings, therapeutics, and clinical outcomes were collected from each case file. Multivariate logistic analysis was adopted to identify the risk factors for deaths. Additionally, the clinical efficacy of dexamethasone treatment was investigated. Results: Seventy-six (42.22%) cases were confirmed with severe COVID-19, while 104 patients (57.78%) were divided into the non-severe group. Fever (56.67%, 102/180) and cough (50.00%, 90/180) were the common symptoms of COVID-19. The death rate was 18.89% (34/180), and severe pneumonia (44.12%, 15/34) and septic shock (23.53%, 8/34) represented the leading reasons for deaths. The older age population, a combination of hypertension and diabetes, the presence of pneumonia, and high levels of inflammatory markers were significantly associated with severity of COVID-19 development (P < 0.05 for all). Altered level of consciousness [odds ratio (OR) = 56.574, 95% confidence interval (CI) 5.645-566.940, P = 0.001], high levels of neutrophils (OR = 1.341, 95%CI 1.109-1.621, P = 0.002) and C-reactive protein (CRP) (OR = 1.014, 95%CI 1.003-1.025, P = 0.016) might be indicators for COVID-19 deaths. Dexamethasone treatment could reduce mortality [30.36% (17/56) vs. 50.00% (10/20)] among severe COVID-19 cases, but the results were not statistically significant (P > 0.05). Conclusions: The development and prognosis of COVID-19 may be significantly correlated with consciousness status, and the levels of neutrophils and CRP.
Author Contributions Bo Tu, Biao Xu, and Weiwei Chen designed, drafted the manuscript. Marta Lado, Reginald Cole, Fang Chu, Susan Hastings-Spaine, and Mohamed Boie Jalloh contributed to the acquisition and analysis of the data. Junjie Zheng, Sulaiman Lakoh, and Stephen Sevalie conceived the manuscript and substantively revised it. All authors revised and approved the final manuscript. of Interest None.
References
Committee, Cnh, Diagnosis and treatment of pneumonia caused by 2019-nCoV (version 7)
Cunningham, Goh, Koh, Treatment of COVID-19: old tricks for new challenges, Crit Care, doi:10.1186/s13054-020-2818-6
Esposito, Noviello, Pagliano, Update on treatment of COVID-19: ongoing studies between promising and disappointing results, Infez Med
Guo, Cao, Hong, The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status, Mil Med Res, doi:10.1186/s40779-020-00240-0
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with covid-19-preliminary report, N Engl J Med, doi:10.1056/NEJMoa2021436
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Kumar, Arora, Sharma, Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.04.044
Lai, Shih, Ko, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105924
Li, Guan, Wu, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, doi:10.1056/NEJMoa2001316
Li, Huang, Wang, COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis, J Med Virol, doi:10.1002/jmv.25757
Lian, Hao, Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China, Influenza Other Resp, doi:10.1111/irv.12758
Liu, Li, Feng, Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China, Crit Care, doi:10.1186/s13054-020-2786-x
Lo, Lio, Cheong, Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau, Int J Biol Sci, doi:10.7150/ijbs.45357
Ludwig, Zarbock, Coronaviruses and SARS-CoV-2: a brief overview, Anesth Analg, doi:10.1213/ANE.0000000000004845
Song, Zhang, Yin, COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2), Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106080
Su, Lai, Comparison of clinical characteristics of coronavirus disease (COVID-19) and severe acute respiratory syndrome (SARS) as experienced in Taiwan, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101625
Tabata, Imai, Kawano, Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30482-5
Tomazini, Maia, Cavalcanti, Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial, JAMA, doi:10.1001/jama.2020.17021
Valencia, Brief review on COVID-19: the 2020 pandemic caused by SARS-CoV-2, Cureus, doi:10.7759/cureus.7386
Wang, Hou, Luo, The laboratory tests and host immunity of COVID-19 patients with different severity of illness, JCI Insight, doi:10.1172/jci.insight.137799
Who, Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected
Wiersinga, Rhodes, Cheng, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA, doi:10.1001/jama.2020.12839
Xu, Ong, Wang, Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines, Mil Med Res, doi:10.1186/s40779-020-00251-x
Xu, Risk factors for severity and mortality in adult patients confirmed with COVID-19 in Sierra Leone: A retrospective study, doi:10.1097/ID9.0000000000000037
Yavuz, Unal, Antiviral treatment of COVID-19, Turk J Med Sci, doi:10.3906/sag-2004-145
Zhand, Jazi, Mohammadi, COVID-19: the immune responses and clinical therapy candidates, Int J Mol Sci, doi:10.3390/ijms21155559
Zheng, SARS-CoV-2: an emerging coronavirus that causes a global threat, Int J Biol Sci, doi:10.7150/ijbs.45053
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit